Drug Information

Drug General Information
Drug ID
D08HOM
Former ID
DNCL002384
Drug Name
ABT-348
Drug Type
Small molecular drug
Indication Hematological malignancies [ICD9: 200-209; ICD10:C81-C86] Phase 2 [525239]
Company
Abbott Laboratories Abbott
Structure
Download
2D MOL

3D MOL
Formula
C25H21FN6O2S
Canonical SMILES
C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C<br />5=CN(N=C5)CCO)N
InChI
1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)
InChIKey
WPHKIQPVPYJNAX-UHFFFAOYSA-N
PubChem Compound ID
46207586
PubChem Substance ID
96061827, 103904272, 120473509, 160682653, 160860799, 162109055, 172232516, 186016864, 198941668, 224611070, 229403186, 242690604, 251962937
Target and Pathway
Target(s) Aurora protein kinase Target Info Modulator [532023]
KEGG Pathway Oocyte meiosis
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
WikiPathways EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteins
References
Ref 525239ClinicalTrials.gov (NCT02478320) Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors.
Ref 532023Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.